Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History SGMO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics SGMO

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Sangamo Therapeutics Inc

SGMO
Current price
0.51 USD +0.027 USD (+5.65%)
Last closed 0.48 USD
ISIN US8006771062
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 125 204 104 USD
Yield for 12 month +29.13 %
1Y
3Y
5Y
10Y
15Y
SGMO
21.11.2021 - 28.11.2021

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California. Address: 501 Canal Blvd, Richmond, CA, United States, 94804

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.10 USD

P/E Ratio

Dividend Yield

Financials SGMO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures SGMO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+57 800 000 USD

Last Year

+176 232 000 USD

Current Quarter

+6 437 000 USD

Last Quarter

+7 551 000 USD

Current Year

+57 800 000 USD

Last Year

-45 325 000 USD

Current Quarter

+6 437 000 USD

Last Quarter

+7 551 000 USD
EBITDA -76 076 800 USD
Operating Margin TTM -460.26 %
Price to Earnings
Return On Assets TTM -46.95 %
PEG Ratio
Return On Equity TTM -257.94 %
Wall Street Target Price 4.10 USD
Revenue TTM 63 756 000 USD
Book Value 0.022 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 1 238.30 %
Dividend Yield
Gross Profit TTM -37 878 800 USD
Earnings per share -0.36 USD
Diluted Eps TTM -0.36 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -124.61 %

Stock Valuation SGMO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.85
Price Sales TTM 1.96
Enterprise Value EBITDA -1.00
Price Book MRQ 24.16

Technical Indicators SGMO

For 52 Weeks

0.37 USD 3.18 USD
50 Day MA 0.53 USD
Shares Short Prior Month 25 671 043
200 Day MA 1.13 USD
Short Ratio 5.16
Shares Short 24 179 412
Short Percent 10.57 %